BOLD
Boundless Bio, Inc.1.1400
+0.0000+0%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
25.52MP/E (TTM)
-Basic EPS (TTM)
-2.66Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Boundless Bio narrowed its Q3 FY2025 net loss to $13.9 million from $16.5 million a year earlier, as operating expenses dropped 19% year-over-year to $15.1 million, driven by a 24% cut in research and development costs to $10.7 million following workforce reductions and the wind-down of underperforming trial arms. The company posted a $0.62 diluted EPS loss, improved from $0.74, with 22.4 million shares outstanding aligning neatly with the calculation. Cash burn eased, leaving $117.6 million in cash and short-term investments at quarter-end, bolstered by $4.2 million in year-to-date interest income yet tempered by no debt and a hefty $49.8 million non-current lease liability. Portfolio focus sharpened on the BBI-355/BBI-825 combo in the POTENTIATE trial and BBI-940's IND push, extending runway into early 2028. No non-GAAP metrics disclosed in the 10-Q. Clinical setbacks loom large, with early trial toxicities potentially derailing progress.
8-K
Q3 loss narrows; trials advance
Boundless Bio reported Q3 2025 net loss of $13.9 million, down from $16.5 million year-over-year, with R&D expenses dropping to $10.7 million amid ongoing enrollment in the BBI-355/BBI-825 combination arm of the POTENTIATE trial. Cash reserves stood at $117.6 million, funding operations through first-half 2028 and proof-of-concept data for both programs. An IND submission for BBI-940 remains on track for a Phase 1 trial start in early 2026. Early-stage trials carry inherent uncertainties.
10-Q
Q2 FY2025 results
Boundless Bio trimmed operating expenses to $17.1M in Q2 FY2025 ended June 30, 2025, down 12.0% y/y from $19.4M, as R&D costs fell 17.1% y/y to $12.2M amid portfolio prioritization that cut BBI-825 monotherapy spending while ramping the BBI-355/BBI-825 combination arm in the POTENTIATE trial. Net loss narrowed to $15.7M or $0.70 per diluted share, from $17.0M or $0.77, buoyed by $1.4M in interest income; YTD, losses eased 3.0% y/y to $31.4M on $34.4M expenses. Cash burn slowed, with operating cash use at $26.4M YTD versus $32.0M y/y, leaving $127.1M in cash and equivalents to fund into H1 2028. No debt burdens the balance sheet. Yet clinical timelines remain unpredictable.
8-K
Boundless Bio advances trials
Boundless Bio opened enrollment for the BBI-355/BBI-825 combination arm in its POTENTIATE trial, targeting synergistic anti-tumor effects in oncogene-amplified cancers without overlapping toxicity. The company selected BBI-940 as a development candidate, eyeing an IND submission in early 2026. Cash reserves hit $127.1 million, funding operations through mid-2028 and proof-of-concept readouts. Yet early-stage risks loom large.
8-K
Annual meeting elects directors
Boundless Bio's stockholders at the June 23, 2025 annual meeting elected Christine Brennan, Ph.D., and Nancy Whiting, Pharm.D., as Class I directors until 2028, with Brennan receiving 9,252,440 for votes against 5,046,258 withheld, and Whiting 9,758,214 for versus 4,540,484 withheld. They also ratified KPMG LLP as independent auditors for the year ending December 31, 2025, with overwhelming support of 17,791,309 for votes. Governance stays steady. No major shifts here.
BBOT
BridgeBio Oncology Therapeutics
11.85-0.15
BCAB
BioAtla, Inc.
0.76-0.01
BDTX
Black Diamond Therapeutics, Inc
2.62-0.03
BNTX
BioNTech SE
92.23-1.52
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
BPTH
Bio-Path Holdings, Inc.
0.08+0.00
CBIO
Crescent Biopharma, Inc.
12.92-0.29
ELTX
Elicio Therapeutics, Inc.
8.15-0.37
ELVN
Enliven Therapeutics, Inc.
16.91-0.26
XBIO
Xenetic Biosciences, Inc.
2.07-0.27